Pages

Search This Blog

Translate

Search Tool




Dec 16, 2019

Health News: Axsome depression drug meets late-stage study goal, shares soar 56%

Reuters Editorial




(Reuters) - Axsome Therapeutics Inc said on Monday its drug succeeded in reducing symptoms of major depressive disorder in a late-stage trial, sending the company’s share soaring 56% before the bell.
The trial results take the company a step closer to acquiring a share of the multi-billion dollar market for depression drugs.
Major depressive disorder is a chronic condition that makes patients feel low, experience guilt and worthlessness. In extreme cases, it may lead to suicide.
Axsome said its oral tablet, AXS-05, improves the communication between brain cells and increases levels of serotonin, noradrenaline and dopamine, all of which help regulate mood.
The company said patients on AXS-05, which has been granted a breakthrough therapy designation by the FDA, showed statistically significant improvement as compared to the placebo on several goals after one week.
Axsome said it would file marketing application for AXS-05 in the second half of 2020.
Apart from major depressive disorder, AXS-05 is being tested for treatment-resistant depression and agitation, associated with Alzheimer’s disease. It is also being developed to help people quit smoking.
Axsome shares were trading at $73.14 in early trading.
Reporting by Vishwadha Chander in Bengaluru; Editing by Vinay Dwivedi

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.